<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Stocks on FinanClub</title>
    <link>https://finan.club/tags/stocks/</link>
    <description>Recent content in Stocks on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Wed, 24 Jan 2024 09:04:31 +0000</lastBuildDate><atom:link href="https://finan.club/tags/stocks/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>APP</title>
      <link>https://finan.club/us/app/</link>
      <pubDate>Wed, 24 Jan 2024 09:04:31 +0000</pubDate>
      
      <guid>https://finan.club/us/app/</guid>
      <description>score:-63
Chances: AppLovin has been hot, and the run higher might have some momentum. AppLovin (APP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company&amp;rsquo;s earnings prospects. Risks: It&amp;rsquo;s always important to assess the risk involved in investing in a company, especially in the volatile tech sector.</description>
    </item>
    
    <item>
      <title>AZN</title>
      <link>https://finan.club/us/azn/</link>
      <pubDate>Tue, 19 Dec 2023 09:06:54 +0000</pubDate>
      
      <guid>https://finan.club/us/azn/</guid>
      <description>score:-135
Chances: AstraZeneca (AZN) closed at $65.95, indicating a +1.77% shift from the previous trading day. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax. The additional supply of RSV shot for infants by AstraZeneca and Sanofi indicates a positive outlook for meeting winter demand.</description>
    </item>
    
  </channel>
</rss>
